secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECISION BIOSCIENCES INC (DTIL)
CIK:        0001357874
Form:       8-K
Filed at:   2021-11-08T23:59:59+00:00
Accession:  0001564590-21-055061
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precision BioSciences appoints Sam Wadsworth and Shari Lisa Piré to Board of Directors
--------------------------------------------------------------------------------

- Sam Wadsworth, Ph.D. (CSO, Ultragenyx Gene Therapy) appointed Class II director; brings 30 years gene therapy experience.
- Shari Lisa Piré, J.D. (Chief Legal & Sustainability Officer, Plume Design) appointed Class III director; over 20 years legal/corporate experience.
- New directors eligible for $40K annual cash retainer, $350K initial equity award vesting over 3 years, plus annual option awards.
- Company states it aims to advance three INDs/CTAs over next three years and continue allogeneic CAR T programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357874/000156459021055061/0001564590-21-055061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357874/000156459021055061/dtil-8k_20211106.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-055061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer